Skip to content
Biotechnology

Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for better bone repair

Monash University 2 mins read

Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates and screws typically used to hold fractured bones together. 

Surgeons routinely use stainless steel or titanium, which stay in the body forever, can cause discomfort and may require follow-up surgeries. A new zinc alloy, designed by Monash biomedical engineers, could solve these problems by being mechanically strong but gentle enough to degrade safely over time while supporting optimal healing.

A study published today in Nature shows the research team’s innovative approach to making the zinc alloy as strong as permanent steel implants and more durable than other biodegradable options like magnesium-based implants.

Lead researcher, Professor Jian-feng Nie, from the Department of Materials Science and Engineering, said the innovative material had the potential to transform orthopaedic care by reducing complications, minimising the need for additional surgeries, and offering a sustainable alternative to permanent metallic implants.

“Our zinc alloy material could revolutionise orthopaedic care – opening the door to safer, smaller implants that not only enhance patient comfort but also promote better healing outcomes by minimising disruption to surrounding tissues,” Professor Nie said.

“An implant that never disappears will always be a risk to the patient. On the other hand, one that degrades too fast won’t allow adequate time for the bones to heal. With our zinc alloy material, we can achieve the optimal balance between strength and controlled degradation of the implant to promote better healing.”

The research shows that by engineering the size and orientation of the material’s grains, the zinc alloy can bend and adapt in unique ways to accommodate the shapes of its neighbouring tissues. 

“This made it not only stronger but more flexible, offering a game-changing alternative for orthopaedics,” Professor Nie said.

The research is paving the way for a new start-up to be launched out of Monash University with a focus on developing next-generation biodegradable implants.

https://doi.org/10.1038/s41586-024-08415-8

-ENDS-

MEDIA ENQUIRIES:

Courtney Karayannis, Media and Communications Manager

Monash University

T: +61 408 508 454 or [email protected] 



Monash University Media | +613 9903 4840 | [email protected] 

Visit Monash Lens for expert insights and commentary

 

Media

More from this category

  • Biotechnology, Business Company News
  • 19/02/2026
  • 22:53
Ecopha Group Inc

Ecopha Group Inc. Recognised as One of the Most Innovative Companies to Watch in 2026 by The CEO Vision.

Key Facts: • Recognised by CEO Vision as one of the Most Innovative Companies to Watch in 2026• Incorporated in Delaware, USA in 2024…

  • Contains:
  • Biotechnology, Medical Health Aged Care
  • 19/02/2026
  • 12:50
Q-Sera

Improving laboratory management and patient outcomes – Q-Sera announces first product launch of its RAPClot(TM) rapid serum blood collection tube technology in Japan

Melbourne, Australia – February 19, 2026 – Q-Sera Pty Ltd, an Australian venture-backed company, today announced that leading Japanese medical device company, Terumo Corporation has launched VenoJect II RAPClotTM evacuated blood collection tubes in the Japanese market. These next-generation tubes incorporate Q-Sera’s patent protected technology and will improve laboratory management and patient outcomes. Even in anticoagulated blood, RAPClot™ rapid serum tubes rapidly produce high quality serum in five minutes. In the case of the VenoJect II RAPClot tubes, formulated to clot up to 6U/ml heparin. This is the first real innovation in the Japanese blood collection tube market in decades,…

  • Biotechnology, Business Company News
  • 12/02/2026
  • 12:22
Jane Morgan Management

BlinkLab Limited (ASX:BB1) Expands Pivotal FDA Trial Network to Nine Elite U.S. Sites Ahead of Imminent Study Commencement

12February 2026 – Sydney, Australia | BlinkLab Limited (ASX:BB1), a leader in AI-powered digital diagnostics, has expanded its U.S. clinical footprint with the onboarding…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.